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INTRODUCTION
Fragile X syndrome is one of themost common forms
of familial mental retardation. Population surveys have
established that the prevalence in males is one in 4,000
and in females approximately one in 6,000 (1). Typical
characteristics inmale patients include long face, promi-
nent chin, large floppy ears, macroorchidism, retarded
language development, hyperactivity and seizures.
In most patients the disease is caused by an expan-
sion of the CGG trinucleotide repeat located in the 5’-
untranslated region of theFMR1 gene (2-4).Thesubse-
quent methylation of the expandedCGG repeat region
and adjacent CpG island results in a lack of expression
of the FMR1 gene (5-7). Normal individuals have ap-
proximately 6-52 CGG repeats, and smaller expansion
of 53 -200 CGG repeats called a premutation can be
detected in carriers. Most patients with fragile X syn-
drome have full expansionwithmore than 200 CGG re-
peats. However a small number of patients have been
found with deletion of all or part of theFMR1 gene (8).
Furthermore, three types of intragenic small mutations
in the FMR1 gene have been found ; one nucleotide sub-
stitution, (9), one nucleotide deletion and two nucleo-
tide substitution (10).
The FMR1 gene, located on chromosome Xq27.3,
spans 38 kb and consists of 17 exons (11).FMR1 codes
for a protein designated as FMRprotein (FMRP). FMRP
is an RNA-binding protein, possessing two RNA-binding
motifs, twoKHdomains and an RGGbox (12, 13). It has
been shown that FMRP indeed binds to RNA in vitro
(14). Several alternatively spliced forms ofFMR1mRNA
are known to exist (11, 15-17) and thegeneproducts vary
in size from 75 to 85 kDa (18-20).
In many patients with fragile X syndrome, the symp-
toms are indistinguishable from autism (21, 22).More-
over, a triplet repeat expantion of the FMR1 has been
found in several patients previouslydiagnosedas autisim
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or “non-specific”mental retardation. The possibility
thus exists that autism and mental retardation are the
result of mutations in theFMR1 gene other than expan-
sion of the CGG repeat. To test this hypothesis, we
screened 76 males and 14 females formutations in the
FMR1 gene using polymerase chain reaction (PCR)-
single strand conformation polymorphism (SSCP).
MATERIALS AND METHODS
Patients
We screened 90 patients (76 male and 14 females)
who were referred to our department for autism or
“non-specific”mental retardation. An informed consent
was obtained according to a guideline from the Ethics
Committee of the University of Tokushima. All patients
were negative for the CGG triplet repeat expansion.
PCR-SSCP analysis
GenomicDNAwas isolated from the peripheralwhite
blood cells of each patient. Using genomic DNA as a
template, all 17 exons were amplified by PCR in a 20-µl
reaction volume. The primers were designed so that the
splice site regions were also analyzed. The sequences
of the primers used for amplification are shown in Table
I. All exons aside from exon 1wereamplifiedusing50ng
genomic DNAwith 20 pmol of eachprimer (forward and
reverse) in a total volume of 20 µl, containing 1.5 mM
MgC12, 0.2 mM dNTP, and 0.5 units of Taq polymerase
(Promega) in 1x PCR buffer (Promega). Amplification
was performed during 40 cycles of denaturing at 94℃
for 20 sec followed by annealing at 53℃ for 1min and
extension at 72℃ for 1 min. Exon 1was amplified in a
total volume of 20µl, containing 50 ng of genomicDNA,
10 pmol of each primer (forward and reverse), 1.5 mM
MgC12, 0.2 mM dNTP, and 0.5 units of Taq polymerase
in the 1x buffer. Amplification was carried out during
40 cycles of denaturing at 94℃ for 20 sec, annealing at
63℃ for 1 min, and extension at 72℃ for 1 min. SSCP
analysis was carried out according to the method of
Oto et al (23). One microliter of the PCR product was
combined with 9 µl of 95% formamide loading dye con-
taining 10 mMNaOH, 0.05% of bromophenol blue and
0.05% of xylene cyanol, was boiled for 5min and imme-
diately chilled on ice. Fivemicroliters of the denatured
DNA was applied onto 10 or 12% polyacrylamide gel
depending on its length (see Table I), and electropho-
resed both at 4℃and at 20℃ in 0.5x TBEbuffer (45mM
Tris-HCl, pH 8.0, 45mMborate, and 1mMEDTA). Fol-
lowing electrophoresis, thegelswere stainedusing silver
staining system (Promega).
Table 1. Primer sequences sizes of the PCR product and concentrations of the acrylamide gel used for SSCP analysis
Exon Forward Reverse
Size
(bp)
Acrylamide gel
concentrations
(%)
１ GCGCTAGCAGGGCTGAAGAG AGGGAAGGAAGGGCGAAGAT １１８ １４
２ CACAAGTTAATTTAACGTTTTTTCTTACA CCTCATCATTAAAATTATATAACGAGACAC １１９ １４
３ CATGTTAAATAATTGTATGTTTGCTTATTT CAGTGCTAAATGACTTTATGGCAG １６３ １２
４ GAAATATTCTGTGTTGTAATTTTTGTGT GAAAAAAATTTAAATAGGCATTTTCCT １３１ １２
５ TTGTGATTAGAAGTGACTTTTATTTATTTC TCAGCATTTCTTGTGTATCAACTT ２０９ １０
６ CTGCATTTATTTATGTCAGTAGTTGGTAA ACTAAAAATAAACAACTCAAAAATGCTC １８７ １０
７ GCCTTGATAATAATGTTGTTAATTTAAATC TAGGTACCCTTACAAGCAGTGCTA １９２ １０
８ TATTCATCAGACGTCCATTTCTCT GGGAAAAAAAAACTATGCAGTAAAATA ２３１ １０
９ TGTCTTAAAATGTTTCCCCTTTTA TGTTGTACTATATGTCAACAGATACTTCTG １４３ １０
１０ TTTTAAAACCAAACTTGATTTATTTATTTC CACAAAATATTCGCACTGTAACAT １７０ １２
１１ GAGCTAAATAAAGTCTTAAATTGGTCCTT TTGTAATTCAAAGTGACAAGTAATTCTT ２２８ １０
１２ GACATCCCTTGCATTCCTTATACT GTGTATTTCTCAAGGAATGTTTTCCT １２２ １２
１３ GATCATTGTTGCAATTTCTTTTTC AGGATTAGAAGTTAAAGTTCTTTCTGTTC １４６ １２
１４ AATGTCAAATTATTTTTACTGTTATCTTGT TAAAGTTACTGAGTAAAATGCTTAGTTTGT ２７１ １０
１５ CAGACAATGGTATATAACTTTTAACTCTCG AGCTGTTACAATTCACTTTGATTTCTT ２６１ １０
１６ TCAGAATCAGTAACTGTTGAACCTTT TAAGATGAAAAGAGGCAGACAGGT １５５ １２
１７ CAGTAGGATATGGTCTGTGTATATAACAAC GGTATAGGAAATATAACTTCAGAATTATGC ２４０ １０
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Sequence Analysis
DNA fragments showing abnormal electrophoretic
mobility were purified using PCR Preps DNA Puri-
fication System (Promega), and directly cloned into a
pGEMT-Easy vector (Promega).Multiple cloneswere
randomly picked up and sequenced using Thermo Se-
quenase Cycle Sequencing Kit (AmershamPharmacia
Biotech) according to themanufacturer’s instructions.
Confirmation of 879 A to G mutation by AhdI digestion
A 273-bp genomic DNA fragment encompassing
nucleotide 34514 in the genomic sequence (847 in the
cDNA) in exon 9 and nucleotide 34786 in intron 9 was
amplified by PCR. The sequences of the forward and re-
verse primers were 5’-aagatgtaatacaagttccaagacacttag
and 5’-caagttagtgggtgcagcgcaccagcat, respectively.
In the forward primer, two nucleotides shown in bold
were substituted so that the mutant DNAwas cleaved
into two fragments (246 bp and 27 bp) by AhdI while
the normal DNA was not digested. PCRwas performed
in a total volume of 50 µl containing 10 pmol of forward
and reverse primers, 50 ng of genomicDNA, 0.2mM
dNTP, 1.5mMMgC12, and 0.5 units of TaqDNApolym-
erase in 1 x PCRbuffer. After purifying thePCRproduct,
the amplified DNA was digested with AhdI and ana-
lyzed on a 1.5% agarose gel.
Reverse-transcription (RT)-PCR and sequencing
Total RNAwas isolated from the patient’s peripheral
white blood cells using SV Total RNA Isolation System
(Promega). Human brain mRNA (OriGene Technolo-
gies) was used as a control. Using these RNAs as a
template, reverse transcription was carried out in a
total volume of 20 µl containing 2 µg of total RNA or
0.1 µg of mRNA, 0.25 µg of random hexamer, 0.5 mM
NTP, 2.5 mMMgCl2, 10 mMDTT, 200 units of Super
Script II RT (Lifetech), and 40 units of RNase inhibitor
in 1 x first-strand buffer. The mixture was incubated
at 25℃ for 10 min and then at 42℃ for 50 min. First-
strand cDNA was directly used for PCR to amplify a
segment encompassing nucleotides 592 and 1219 of
the FMR1 cDNA. After column purification, the PCR
product was subcloned en mass into a plasmid and
sequenced as detailed above.
RESULTS AND DISCUSSION
Using PCR-SSCP analysis, we screened all 17 exons
of the FMR1 gene in 90 children (76 males and 14 fe-
males) who were referred to us for autism or mental
retardation. In order to enhance the sensitivity of de-
tecting mutations, the amplified exonswere run at two
different temperatures, 4℃ and 20℃. No mutations
were found in male individuals, suggesting that muta-
tions of theFMR1 are not a common causeof autismor
mental retardation. However, abnormal electrophoretic
mobility was observed in one sample, exon 9 from an
autistic female (Fig.1). This abnormality was detected
on the gel run at 4℃, but not detected on the gel run at
20℃.
The patient in whom the abnormality was found
was a 15-year old female. Hermother had of a normal
pregnancy and shewas deliveredwithout complication.
Her developmental milestones were normal until one
year of age, when a psychomotor delay was first noted.
At three years of age she was referred to our hospital
for delayed speech. She presented as a remote child
with poor eye contact. At nine years of age, focal spikes
were noted in themid-frontal region on electroencepha-
logram and carbamazepine therapy was initiated. At
11 years of age, she met the International Classification
of Diseases criteria for autism.Whenshewas examined
at 14 years of age, she had severe mental retardation
with an IQ below 20, and her ChildhoodAutismRating
Scale (CARS) was 34.5 suggesting that she wasmod-
erately autistic.
To characterize the mutation found in exon 9 of the
Fig. 1. PCR-SSCP analysis of exon 9 of the FMR 1 gene. The
samples were run on a 10% agarose gel at 4℃. Arrowhead indicates
the band that showed an anomalous migration.
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patient, the fragment was amplified by a new round of
PCR and the amplified fragment was cloned into a vec-
tor. Seventeen clones carrying exon 9were sequenced.
Ten clones had an A to C transversion at nucleotide
879 (Fig. 2A), whereas the remaining seven had a
normal sequence, suggesting that the patient was a
heterozygote of the normal sequence and 879 A to C
transversion. This was confirmed by Ahd I digestion
of the PCR product (Fig. 2B). This mutation was not
found in 50 normal controls. Although this nucleotide
substitution did not result in any change of the amino
acid sequence, the posibility exists that this mutation
affected splicing of theFMR1 premRNA,given that 879
A is the second last nucleotide in exon 9. To explore this
possibility, total RNA was isolated from the patient’s
peripheral blood cells. Total RNA fromhumanbrainwas
used as a control. The RNAs were reverse-transcribed,
and a segment encompassing exon 7 (nucleotide 592)
and exon 13 (nucleotide 1219) was amplified byPCR.As
shown in Figure 3, two distinct bands were observed
in normal controls. When these products were cloned
and sequenced, three clones out of 12 had a normal
sequence, whereas in the remaining nine clones, the
entire exon 12 was skipped. This alternative splicing
has been found in past studies, and it is not considered
to be pathogenic (15, 17). The electrophoretic pattern
of the DNA fragments amplified from the patient’s total
RNA were markedly different from that of the normal
control. At least three distinct bandswith different sizes
were visible on as 1% agarose gel. After purifying the
DNA using a column, this PCR product was directly
subcloned en mass into a vector, and 36 clones were
randomly picked up and sequenced. The results are
shown in Figure 4. Among 36 clones, six clones had
an A at nucleotide 879 and the remaining 30 clones
had a C at 879, suggesting that the mutant allele is
preferentially transcribed in the patient’s white blood
cells. In six clones with a normal sequence, only one
clone had exon 12. In 30 clones which had an 879 A to
C transversion, two different sequenceswere observed,
aside from the difference caused by the alternative splic-
ing of exon 12. In seven clones out of 30, an 879 A to C
transversion was the only mutation (only two clones
had exon 12). This type of mRNA resulted in FMRP
with a normal amino acid sequence. In 23 clones, how-
ever, the first 47 nucleotides of intron 9 were inserted
between exon 9 and exon 10 (only five clones had exon
12). In all clones with the 47-bp insertion, an 879 A to
C transversion was found. Since 879 Awas the second
last nucleotide of exon 9, which is highly conserved
Fig. 2. A : Sequence analysis of exon 9 showing abnormal migration in PCR-SSCP analysis. Two types of sequence were
detected normal and 879 A to C transversion (asterisk). B : Ahd I digestion of exon 9 in the control and patient. The control
fragment (273 bp) was not cut by Ahd I whereas approximately half of the fragment amplified from patient’s genomic DNA was
digested into two segments (246 bp and 27 bp). The shorter 27 bp segment was not visible on the gel.
Fig. 3. RT-PCR products from control human brain mRNA and
patient’s total RNA. Lane 1 human brain mRNA; lane 2 total RNA
from the patient.
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in the splice donor site (24, 25), the likelihoodwashigh
that the original splice donor site was inactivatedand the
cryptic splice donor site was in turn activated (Fig. 5A).
When this type of mutant mRNA is translated, a pre-
mature termination of the protein synthesis occurs and
the product protein lacks the second KH domain and
RGG box (Fig. 5B). Given that KH domains and RGG
box are essential for RNA binding of the FMRP (12,
14, 26), we assumed that RNA binding of the truncated
protein was impaired. Supporting our hypothesis, a pa-
tient in a previous study was found to have a missense
mutation in the secondKHdomain (9), and in vitro stud-
ies have shown that the mutated FMRP has a reduced
RNA binding capacity (14).
We cloned the total amplified transcripts en mass
into a cloning vector and sequenced 36 randomly picked
clones. It has been shown that the number of clones
of each splicing isotope reflect the abundance of each
type of transcript (27). Judging from the number of
clones obtained after RT-PCR ofFMR1mRNA, themu-
tant allele was predominantly transcribed, and a large
proportion of the transcripts from the mutant allele
were aberrantly spliced. Approximately 64% of the total
FMR1 transcripts underwent aberrant splicing. It has
been suggested that molecular findings in white blood
cells may not accurately represent the picture in the
Fig. 4. Sequence analysis of the RT-PCR products in the patient. Thirty-six clones were sequenced and three different types
were observed;normal (A) 879 A to C transversion (B) and 879 A to C transversion＋insertion of first 47 bp of intron 9 between
exon 9 and exon 10 (C). In addition exon 12 was either present or absent in all three species due to alternative splicing.
Numerals below the electropherogram indicate ; total number of clones (number of clones with exon 12/number of clones
without exon 12).
Fig. 5. A : Possible mechanism of aberrant splicing caused by 879 A to C transversion. Due to the mutation, original splicing
donor site was “inactivated” and as a result a cryptic splicing donor site in intron 9 (underlined) was “activated.” Consensus
donor site sequence is shown underneath the FMR1 sequence. The predicted amino acid sequence translated from aberrantly
spliced FMR1 mRNA is shown at the bottom (FMRP). B : Schematic representation of the normal full-length FMR1 protein
(FMRP wild-type) and the truncated FMR1 protein (FMRP truncated) deduced to be expressed in the patient. Two KH
domains and an RGG domain which play critical role in RNA binding are shown in gray.
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brain of patients with fragile X syndrome (28), but it is
likely that the amount of normal FMRP is decreased
in the central nervous system which causes autistic
features in the patient.
Symptoms of female heterozygotes who carry a nor-
mal number of CGG triplet repeats in one allele and a
full expansion (more than 200) of the CGG repeat in
another allele have been characterizedsqrd (28-30).
These patients present with awide variety of symptoms
ranging from normal to severe mental retardation.
Between 25 and 50 % of females with the full mutation
demonstrate mental retardation (IQ<70), whereas about
25% of these females present with a borderline IQ (be-
tween 70and 84). The remaining 25% to 50% have a
normal IQ (85). A relationship between the ratio
of active normal X chromosomes to normal inactive
chromosomes and the severity of mental retardation
has been reported (31, 32), whereas the relationship
between the number of triplet repeats and IQ remains
controversial (28, 33). Our patient had severemental
retardation and moderate autistic features, suggesting
that relatively large proportion of the normal alleles
were inactive in her neuronal cells.
In conclusion, mutations inFMR1 are not commonly
found in patients with autism or mental retardation.
However, the possibility exists that FMR1mutations
are a cause of autism or mental retardation in a small
number of patients. Future studies need to be carried
out on large number of individuals and should include
female patients.
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